Stelo By Dexcom First Glucose Biosensor To Be Cleared By FDA As Over-The-Counter

-2.87%

DexCom, Inc.

DXCM

66.96

-2.87%

Stelo will be the first glucose biosensor in the US cleared for use without a prescription
Indicated for use for people 18 years and older who are not using insulin therapy
A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user's smartphone†
Created by the makers of Dexcom G7, the most accurate,1 easy-to-use2 and clinically-proven CGM brand,3-7 Stelo will empower even more people with Type 2 diabetes not using insulin to take control of health
- Stelo will be available summer of 2024

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.